Helicobacter pylori DNA vaccine - Valentis

Drug Profile

Helicobacter pylori DNA vaccine - Valentis

Latest Information Update: 03 Apr 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valentis
  • Developer Baylor College of Medicine; M. D. Anderson Cancer Center; Valentis
  • Class Bacterial vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Helicobacter infections

Most Recent Events

  • 03 Apr 2002 Discontinued - Preclinical for Helicobacter infections in USA (unspecified route)
  • 22 Jun 1999 The GeneMedicine/Megabios merged company is now called Valentis
  • 29 Mar 1999 GeneMedicine has merged with Megabios
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top